Neurocrine Biosciences Price Target Raised to $19.00 at Oppenheimer (NBIX)
Equities researchers at Oppenheimer boosted their price target on shares of Neurocrine Biosciences (NASDAQ:NBIX) from $15.00 to $19.00 in a research report issued on Monday, AR Network reports. The firm currently has an “outperform” rating on the stock. Oppenheimer’s price target would suggest a potential upside of 12.09% from the stock’s previous close.
Several other analysts have also recently commented on the stock. Analysts at Roth Capital raised their price target on shares of Neurocrine Biosciences from $22.00 to $24.00 in a research note to investors on Friday. Separately, analysts at MKM Partners raised their price target on shares of Neurocrine Biosciences from $17.00 to $20.00 in a research note to investors on Friday. They now have a “buy” rating on the stock. Finally, analysts at Cowen and Company raised their price target on shares of Neurocrine Biosciences from $19.00 to $20.00 in a research note to investors on Friday. Two investment analysts have rated the stock with a hold rating and eight have assigned a buy rating to the company. The stock has an average rating of “Buy” and an average price target of $19.90.
Shares of Neurocrine Biosciences (NASDAQ:NBIX) traded down 2.30% during mid-day trading on Monday, hitting $16.56. The stock had a trading volume of 143,402 shares. Neurocrine Biosciences has a 52 week low of $8.57 and a 52 week high of $20.29. The stock’s 50-day moving average is $15.48 and its 200-day moving average is $12.49. The company’s market cap is $1.115 billion.
Neurocrine Biosciences (NASDAQ:NBIX) last announced its earnings results on Thursday, February 6th. The company reported ($0.16) earnings per share for the quarter, beating the analysts’ consensus estimate of ($0.17) by $0.01. The company had revenue of $0.73 million for the quarter, compared to the consensus estimate of $0.79 million. During the same quarter last year, the company posted $0.14 earnings per share. Neurocrine Biosciences’s revenue was down 96.7% compared to the same quarter last year. On average, analysts predict that Neurocrine Biosciences will post $-0.46 earnings per share for the current fiscal year.
Neurocrine Biosciences, Inc (NASDAQ:NBIX) discovers, develops and commercializes drugs for the treatment of neurological and endocrine-related diseases and disorders.
Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.